| Rogers to Become Majority Owner of Maple Leaf Sports & Entertainment |
Globe Newswire |
09/18 |
08:30 |
| Verizon Business partners with Monumental Sports & Entertainment to maintain its best-in-class, tech-forward leadership at Capital One Arena |
Globe Newswire |
09/17 |
14:00 |
| Props.Cash Bolsters Responsible Gaming Offering with Birches Health Partnership |
Globe Newswire |
09/16 |
11:20 |
| Jet.AI Shareholder Webinar on Thursday September 19th at 2pm EST |
Globe Newswire |
09/16 |
08:30 |
| Verizon Business’ award-winning Innovation Sessions head back to the nation’s capital |
Globe Newswire |
09/13 |
13:00 |
| Jet.AI Opens New JetLeg.AI app to Beta Testers |
Globe Newswire |
09/13 |
10:00 |
| The BIG 615’s Storme Warren Honored by The Charlie Daniels Journey Home Project For His Work with Veteran Causes |
Globe Newswire |
09/12 |
18:17 |
| Ottawa Senators team up with Calian as the official road jersey sponsor |
Globe Newswire |
09/12 |
10:05 |
| Verizon Business to showcase 5G’s role in transforming content creation and distribution at IBC2024 |
Globe Newswire |
09/12 |
09:00 |
| Jet.AI Provides Encouraging Updates Around its Software Solutions |
Globe Newswire |
09/11 |
10:00 |
| Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma |
Globe Newswire |
09/10 |
08:30 |
| NFL Taps TuneIn to Host International Audio Coverage for the 2024 Season |
Globe Newswire |
09/05 |
10:01 |
| DraftKings Announces Jason Robins’ Participation in Upcoming Event |
Globe Newswire |
09/04 |
16:30 |
| Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma) |
Globe Newswire |
09/03 |
08:30 |
| Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML |
Globe Newswire |
09/03 |
08:00 |
| Big 12 Conference and TuneIn Launch ‘Big 12 Radio’ to Bring College Sports Fans Non-Stop Conference Coverage |
Globe Newswire |
08/27 |
09:00 |
| Sportradar Announces Upcoming Investor Conference Participation Schedule |
Globe Newswire |
08/27 |
08:00 |
| Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024 |
Globe Newswire |
08/27 |
07:00 |
| Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma |
Globe Newswire |
08/26 |
07:00 |
| TuneIn Ramps Up Division 1 College Football Coverage for the 2024-2025 Season |
Globe Newswire |
08/23 |
14:04 |
| Jet.AI Announces Entry Into Warrant Amendments After Successful Warrant Exchange Offer and Consent Solicitation |
Globe Newswire |
08/23 |
08:05 |
| Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma |
Globe Newswire |
08/23 |
01:00 |
| Catapult Launches Live In Game Video Solutions with the SEC |
Globe Newswire |
08/20 |
07:00 |
| TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma |
Globe Newswire |
08/19 |
14:00 |
| Mantle Cell Lymphoma Treatment Market is Projected to Reach US$ 5.77 Billion by 2034, with a 8.6% CAGR | Fact.MR Report |
Globe Newswire |
08/15 |
10:30 |
